WO1999013898A1 - Ec-3 en tant qu'inhibiteur des integrines alpha4 beta1 et alpha4 beta7 - Google Patents

Ec-3 en tant qu'inhibiteur des integrines alpha4 beta1 et alpha4 beta7 Download PDF

Info

Publication number
WO1999013898A1
WO1999013898A1 PCT/US1998/016719 US9816719W WO9913898A1 WO 1999013898 A1 WO1999013898 A1 WO 1999013898A1 US 9816719 W US9816719 W US 9816719W WO 9913898 A1 WO9913898 A1 WO 9913898A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
cells
integrin
protein
substantially purified
Prior art date
Application number
PCT/US1998/016719
Other languages
English (en)
Other versions
WO1999013898A9 (fr
Inventor
Stefan Niewiarowski
Cezary Marcinkiewicz
Original Assignee
Stefan Niewiarowski
Cezary Marcinkiewicz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stefan Niewiarowski, Cezary Marcinkiewicz filed Critical Stefan Niewiarowski
Priority to US09/485,323 priority Critical patent/US6818617B1/en
Publication of WO1999013898A1 publication Critical patent/WO1999013898A1/fr
Publication of WO1999013898A9 publication Critical patent/WO1999013898A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • This invention generally relates to methods and compositions for modulating cell adhesion and for inhibiting the interaction between integrins and their ligands.
  • the invention relates to peptides that selectively inhibit ⁇ 4 integrins.
  • Another preferred embodiment of the invention is a method of inhibiting the interaction between cells expressing an ⁇ 4 integrin and MadCAM-1 in a patient in need of such treatment comprising administration of a therapeutically effective amount of a composition comprising a pharmaceutically acceptable carrier and a protein or peptide according to the invention.
  • MLD is the one letter designation of the amino acid sequence Met-Leu-Asp, which occurs in the EC-3 protein.
  • EXAMPLE 3 Purification of EC-3
  • the venom fraction eluting at approx. 40% and designated EC3 was purified to homogeneity by two steps of reverse phase HPLC using a C-18 column.
  • proteins from crude venom were separated as in Example 2.
  • the column was eluted with an acetonitrile linear gradient 0-80% over 45 minutes, and the EC3 fraction eluting at approximately 40% of acetonitrile was collected, lyophilized, and dissolved in water.
  • the recovery of protein after the first step was 7 mg per 1 g of dried venom.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Identification, purification et caractérisation d'une nouvelle désintégrine hétérodimère, EC-3, tirée du venin de la vipère Echis carinatus. EC-3 inhibe les intégrines α-4 d'une manière indépendante de RGD. La présente invention concerne en outre des procédés d'utilisation de EC-3, ou d'un fragment ou dérivé biologiquement actif de ladite substance, pour inhiber l'interaction entre des cellules exprimant les intégrines α4 et des ligands cellulaires.
PCT/US1998/016719 1997-08-15 1998-08-13 Ec-3 en tant qu'inhibiteur des integrines alpha4 beta1 et alpha4 beta7 WO1999013898A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/485,323 US6818617B1 (en) 1997-08-15 1998-08-13 EC-3, an inhibitor of α4β1 and α4β7 integrins

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5582597P 1997-08-15 1997-08-15
US60/055,825 1997-08-15
US5595797P 1997-08-18 1997-08-18
US60/055,957 1997-08-18

Publications (2)

Publication Number Publication Date
WO1999013898A1 true WO1999013898A1 (fr) 1999-03-25
WO1999013898A9 WO1999013898A9 (fr) 1999-09-30

Family

ID=26734666

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/016719 WO1999013898A1 (fr) 1997-08-15 1998-08-13 Ec-3 en tant qu'inhibiteur des integrines alpha4 beta1 et alpha4 beta7

Country Status (2)

Country Link
AU (1) AU9614298A (fr)
WO (1) WO1999013898A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116760B2 (en) 2018-10-30 2021-09-14 Gilead Sciences, Inc. Quinoline derivatives
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
US11224600B2 (en) 2018-10-30 2022-01-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SIIGUR et al., "cDNA Cloning and Deduced Amino Acid Sequence of Fibrinolytic Enzyme (Lebetase) from Vipera Lebetina Snake Venom", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, Vol. 224, No. 1, pages 229-236. *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116760B2 (en) 2018-10-30 2021-09-14 Gilead Sciences, Inc. Quinoline derivatives
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
US11224600B2 (en) 2018-10-30 2022-01-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin

Also Published As

Publication number Publication date
AU9614298A (en) 1999-07-01
WO1999013898A9 (fr) 1999-09-30

Similar Documents

Publication Publication Date Title
US6818617B1 (en) EC-3, an inhibitor of α4β1 and α4β7 integrins
CA2059124C (fr) Inhibiteurs d'agregation de plaquettes
McDowell et al. Mambin, a potent glycoprotein IIb-IIIa antagonist and platelet aggregation inhibitor structurally related to the short neurotoxins
US5843897A (en) Platelet aggregation inhibitors
Huang et al. Trigramin: primary structure and its inhibition of von Willebrand factor binding to glycoprotein IIb/IIIa complex on human platelets
AU682561B2 (en) Novel integrin-binding peptides
AU666853B2 (en) Platelet aggregation inhibitors having high specificity for GP IIbIIIa
JP3556215B2 (ja) 組換えトロンビンレセプターおよびそれに関連した薬剤
IE84069B1 (en) Recombinant thrombin receptor and related pharmaceuticals
CA2092315A1 (fr) Inhibiteurs de l'agregation plaquettaire
WO1999013898A1 (fr) Ec-3 en tant qu'inhibiteur des integrines alpha4 beta1 et alpha4 beta7
EP1044012B1 (fr) Inhibition de l'angiogenese au moyen d'analogues de peptide du domaine 5 de la kininogene de poids moleculaire eleve
AU636159C (en) Platelet aggregation inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1998967164

Country of ref document: EP

AK Designated states

Kind code of ref document: A1

Designated state(s): US

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): US

COP Corrected version of pamphlet

Free format text: REQUEST FOR RECTIFICATION UNDER RULE 91.1(F), ADDED (4 PAGES)

WWW Wipo information: withdrawn in national office

Ref document number: 1998967164

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09485323

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: CA